Olaparib 150 mg: Bangladeshi Brands for Bulk Export

Last Updated: August 2026

Published by: Orio Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.

Medical Review: Reviewed by Dr. Nusrat Jahan, MBBS, MD (Medical Oncology)

Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from DRA and DGDA (Directorate General of Drug Administration, Bangladesh).

Sources: accessdata.fda.gov, accessdata.fda.gov, accessdata.fda.gov, ema.europa.eu, drugs.com, alpha-medicare.com

Olaparib — Olaparix, Olakin, Parib, Olarigen, Inpoza, Olanib
Olaparib — Olaparix, Olakin, Parib, Olarigen, Inpoza, Olanib

Key Takeaways

  • Olaparib is a PARP inhibitor (PARP1, PARP2, PARP3) that blocks DNA repair, leading to cell death in BRCA-mutated cancer cells through synthetic lethality.
  • It is approved for adults aged 18 and above for maintenance treatment of BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer following response to platinum-based chemotherapy, and for metastatic castration-resistant prostate cancer in combination with abiraterone and prednisone or prednisolone.
  • Six Bangladeshi-manufactured brands are available — Olaparix, Olakin, Parib, Olarigen, Inpoza, and Olanib — each produced by a distinct licensed manufacturer.
  • Common side effects include nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, dyspepsia, cough, abdominal pain, and neutropenia, while serious risks include MDS/AML and pneumonitis.
  • In Pakistan, these Olaparib brands are imported, Bangladeshi-manufactured products distributed under Drug Regulatory Authority of Pakistan (DRA) oversight through licensed importers and pharmacies.
  • Bulk supply is coordinated directly with named Bangladeshi manufacturers for licensed distributors and hospital procurement teams in Pakistan, with additional shipping available to India and the United Arab Emirates.

About Us — Bangladeshi Pharmaceutical Export Partner

We are a Bangladesh-based B2B pharmaceutical supplier specializing in the export of oncology and specialty medicines to regulated and emerging markets. Our core focus is Pakistan, where we support licensed distributors, hospital pharmacies, and importers with reliable access to Bangladeshi-manufactured antineoplastic agents, including PARP inhibitors such as Olaparib. We also fulfill orders for buyers in India and the United Arab Emirates, extending the reach of quality Bangladeshi pharmaceutical manufacturing across South Asia and the Gulf region.

Our sourcing model is built on a strict principle: we work exclusively with established Bangladeshi manufacturers, never with brands produced outside Bangladesh. This gives our partners a consistent, traceable supply chain and a single point of accountability for product origin. We coordinate directly with manufacturers to manage export documentation, shipment scheduling, and order fulfillment for institutional and wholesale buyers. Our internal procurement review process cross-checks each manufacturer’s export licensing and product registration status before any brand is added to our catalog, and this verification is repeated periodically as part of ongoing supplier due diligence. For pharmacies, hospital procurement teams, and importers in Pakistan seeking a dependable oncology drug export partner, we provide a streamlined channel for bulk Olaparib sourcing backed by manufacturer-level supply relationships.

Olaparib — Olaparib: Composition and Available Brands
Olaparib — Olaparib: Composition and Available Brands

Olaparib: Composition and Available Brands

Olaparib is the active pharmaceutical ingredient in a class of antineoplastic agents known as PARP inhibitors. It is formulated as a film-coated oral tablet and is supplied in this market exclusively through Bangladeshi-manufactured brands. We source and export six brands of Olaparib tablets, each manufactured by a distinct, established Bangladeshi pharmaceutical company:

  • Olaparix — manufactured by Drug International Ltd.
  • Olakin — manufactured by Beacon Pharmaceuticals Ltd.
  • Parib — manufactured by Drug International Ltd.
  • Olarigen — manufactured by General Pharmaceuticals Ltd.
  • Inpoza — manufactured by Genvio Pharma Ltd.
  • Olanib — manufactured by Everest Pharmaceutical Ltd.

These brands are available in 100 mg and 150 mg tablet strengths, consistent with standard Olaparib tablet formulations used internationally. Each brand represents an independently manufactured product line, allowing procurement teams in Pakistan flexibility in selecting a supply source while maintaining assurance that all products originate from licensed Bangladeshi pharmaceutical facilities. As a therapeutic class, PARP inhibitors represent a targeted approach to oncology treatment, and Olaparib remains one of the most established molecules within this category for the indications described later in this article.

Readers should note that strength availability and packaging configurations can vary by manufacturing batch. Distributors and procurement teams are encouraged to confirm current specifications directly with the manufacturer or with our team prior to finalizing an order.

Olaparib — How Olaparib Works
Olaparib — How Olaparib Works

How Olaparib Works

Olaparib functions as an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, specifically PARP1, PARP2, and PARP3. These enzymes play a central role in normal cellular processes, including DNA transcription and the repair of single-strand DNA damage. By inhibiting PARP activity, Olaparib interferes with the cell’s ability to repair damaged DNA through this pathway.

In cells carrying BRCA mutations, which already have impaired homologous recombination DNA repair, PARP inhibition compounds the deficit in repair capacity. This combined disruption drives the concept of synthetic lethality, in which the cancer cell — unable to repair accumulating DNA damage through either pathway — undergoes cell death. This mechanism underlies the rationale for using Olaparib in tumors associated with BRCA mutations and related DNA repair deficiencies. This mechanism of action is well documented in the peer-reviewed oncology literature and is consistent with the pharmacological basis described in international prescribing information for Olaparib-containing products.

Approved Indications and Clinical Use

Olaparib tablets are approved for multiple oncology indications, including ovarian, breast, prostate, and pancreatic cancers, all restricted to adult patients aged 18 years and above. The first is maintenance treatment in adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to first-line platinum-based chemotherapy. This addresses a well-established question in oncology practice regarding Olaparib’s role in ovarian cancer: yes, it is approved specifically as a maintenance therapy following favorable response to platinum-based chemotherapy in patients with confirmed BRCA mutations.

The second approved indication is for the treatment of adult patients with metastatic castration-resistant prostate cancer, used in combination with abiraterone and prednisone or prednisolone, in the European Union for patients in whom chemotherapy is not clinically indicated (with the FDA approval limited to patients with BRCA-mutated mCRPC). This combination-based use reflects Olaparib’s expanded role beyond gynecologic oncology into genitourinary cancer management.

Across both indications, Olaparib is intended for use under the supervision of a qualified oncologist, with treatment decisions guided by BRCA mutation status, prior treatment response, and overall clinical presentation. Specific dosing and treatment duration are determined entirely by the treating physician in accordance with official prescribing information. As with any oncology therapeutic, BRCA mutation testing and eligibility confirmation should be completed by a qualified laboratory and clinical team prior to treatment initiation.

Olaparib — Side Effects and Safety Considerations
Olaparib — Side Effects and Safety Considerations

Side Effects and Safety Considerations

These effects are frequently reported and are typically monitored throughout the course of treatment by the prescribing physician.

More serious risks associated with Olaparib include myelodysplastic syndrome and acute myeloid leukemia (MDS/AML), a rare but serious complication observed in clinical studies, with a notable proportion of reported cases proving fatal. Pneumonitis has also been identified as a serious risk requiring clinical vigilance. Because Olaparib is metabolized primarily through the CYP3A4 pathway, co-administration with strong CYP3A4 inhibitors or inducers can meaningfully affect drug exposure, making a full medication history essential before treatment initiation.

Given the complexity of this safety profile, all monitoring parameters, laboratory follow-up, and dose adjustments must be managed directly by the treating physician in line with official prescribing information. This article does not substitute for individualized clinical guidance, and it is not intended to direct or influence clinical decision-making. It is written for licensed distributors, importers, and procurement professionals evaluating supply sources, not as a substitute for the prescribing physician’s judgment or the official product labeling issued by each manufacturer.

Olaparib — Regulatory Status in Pakistan
Olaparib — Regulatory Status in Pakistan

Regulatory Status in Pakistan

In Pakistan, oncology pharmaceuticals such as Olaparib fall under the regulatory oversight of the Drug Regulatory Authority of Pakistan (DRAP, dra.gov.pk), which governs the registration, import, and distribution of medicines within the country.

No claim of local manufacture within Pakistan is made or implied; these products are supplied strictly as imported, Bangladeshi-manufactured pharmaceuticals, consistent with applicable Pakistani import regulations. Buyers and institutions are encouraged to verify current registration and import documentation requirements directly with the DRA and their designated import compliance teams before finalizing procurement, as registration status and documentation requirements are subject to periodic regulatory updates.

Olaparib — Bulk Ordering, Shipping & Distribution for Licensed Buyers
Olaparib — Bulk Ordering, Shipping & Distribution for Licensed Buyers

Bulk Ordering, Shipping & Distribution for Licensed Buyers

Our export process is designed for licensed distributors, importers, and hospital procurement departments seeking consistent bulk supply of Olaparib tablets. Orders are coordinated directly with the manufacturing partners listed above — Drug International Ltd., Beacon Pharmaceuticals Ltd., General Pharmaceuticals Ltd., Genvio Pharma Ltd., and Everest Pharmaceutical Ltd. — ensuring traceability from production through export.

Olaparib tablets are supplied in standard manufacturer packaging appropriate for 100 mg and 150 mg strengths, with documentation provided to support customs clearance and regulatory review in the destination market. Order quantities are structured around institutional and wholesale requirements rather than single-patient dispensing, and our team works with buyers to align shipment volumes with import licensing and storage capacity.

While our primary market focus is Pakistan, we also accommodate shipping requests from licensed buyers in India and the United Arab Emirates. All cross-border shipments are handled in accordance with the import and documentation requirements of the receiving country, and buyers remain responsible for confirming local registration status with their own regulatory authorities. Interested distributors and procurement teams are invited to contact us directly for current availability across brands and strengths.

Why Choose Us as Your Olaparib Supplier

Our position as a supplier is defined by exclusive sourcing from named Bangladeshi manufacturers — Drug International Ltd., Beacon Pharmaceuticals Ltd., General Pharmaceuticals Ltd., Genvio Pharma Ltd., and Everest Pharmaceutical Ltd. This focused sourcing model allows us to maintain consistent quality oversight and a transparent supply chain for every brand we export, from Olaparix to Olanib.

Globally, Olaparib is recognized under the originator brand Lynparza, which established the clinical profile that Bangladeshi manufacturers now produce under their own registered brand names for export markets like Pakistan. Our role is to provide licensed buyers with dependable, compliance-driven access to these Bangladeshi-manufactured alternatives, backed by direct manufacturer relationships and consistent export documentation. For distributors and pharmacies seeking a long-term oncology supply partner, we offer the reliability and transparency that bulk procurement demands, along with responsive communication throughout the ordering, documentation, and shipping process.

Frequently Asked Questions

What type of cancer is olaparib used for?

Olaparib is approved for maintenance treatment of BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who responded to first-line platinum-based chemotherapy, and for metastatic castration-resistant prostate cancer when combined with abiraterone and prednisone or prednisolone.

Is olaparib approved for ovarian cancer?

Yes, Olaparib is approved as a maintenance therapy for adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to first-line platinum-based chemotherapy.

What are the most common side effects of olaparib?

The most commonly reported side effects include nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, dyspepsia, cough, abdominal pain, and neutropenia.

More serious risks such as myelodysplastic syndrome/acute myeloid leukemia and pneumonitis have also been reported, so treatment should always be monitored by a qualified oncologist.

How does olaparib work against BRCA-mutated cancers?

Olaparib inhibits PARP1, PARP2, and PARP3 enzymes, which are needed for normal DNA repair processes within cells.

In cells with BRCA mutations, which already have impaired DNA repair capacity, this additional inhibition drives a process called synthetic lethality, causing cancer cells to accumulate damage they cannot repair and ultimately die.

Which Olaparib brands are available for bulk export to Pakistan?

We export six Bangladeshi-manufactured Olaparib brands: Olaparix, Olakin, Parib, Olarigen, Inpoza, and Olanib, each produced by a distinct established Bangladeshi pharmaceutical manufacturer.

These are available in 100 mg and 150 mg tablet strengths for licensed distributors, importers, and hospital procurement teams.

Can procurement teams outside Pakistan also order these Olaparib brands?

Yes, while our primary market focus is Pakistan, we also accommodate shipping requests from licensed buyers in India and the United Arab Emirates.

All orders are coordinated directly with the named Bangladeshi manufacturers to ensure traceability and proper export documentation for customs and regulatory review.

  1. 1. www.accessdata.fda.gov
  2. 2. www.accessdata.fda.gov
  3. 3. www.accessdata.fda.gov
  4. 4. www.ema.europa.eu
  5. 5. www.drugs.com
  6. 6. www.alpha-medicare.com

Access This Medicine Through Orio Pharma

We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.

We do not publish prices online. All pricing is provided directly by our specialist supply team on request.

Need any medicine?💬